LC-MS/MS Identification of a Bromelain Peptide Biomarker from Ananas comosus Merr by Secor, Eric R. et al.
University of Connecticut
OpenCommons@UConn
UCHC Articles - Research University of Connecticut Health Center Research
12-2012
LC-MS/MS Identification of a Bromelain Peptide
Biomarker from Ananas comosus Merr
Eric R. Secor
University of Connecticut School of Medicine and Dentistry
Steven M. Szczepanek
University of Connecticut School of Medicine and Dentistry
Linda Guernsey
University of Connecticut School of Medicine and Dentistry
Prabitha Natarajan
University of Connecticut School of Medicine and Dentistry
Karim Rezaul
University of Connecticut School of Medicine and Dentistry
See next page for additional authors
Follow this and additional works at: https://opencommons.uconn.edu/uchcres_articles
Part of the Alternative and Complementary Medicine Commons
Recommended Citation
Secor, Eric R.; Szczepanek, Steven M.; Guernsey, Linda; Natarajan, Prabitha; Rezaul, Karim; Han, David K.; Thrall, Roger S.; and
Silbart, Lawrence K., "LC-MS/MS Identification of a Bromelain Peptide Biomarker from Ananas comosus Merr" (2012). UCHC
Articles - Research. 119.
https://opencommons.uconn.edu/uchcres_articles/119
Authors
Eric R. Secor, Steven M. Szczepanek, Linda Guernsey, Prabitha Natarajan, Karim Rezaul, David K. Han,
Roger S. Thrall, and Lawrence K. Silbart
This article is available at OpenCommons@UConn: https://opencommons.uconn.edu/uchcres_articles/119
Hindawi Publishing Corporation
Evidence-Based Complementary and Alternative Medicine
Volume 2012, Article ID 548486, 10 pages
doi:10.1155/2012/548486
Research Article
LC-MS/MS Identification of a Bromelain Peptide Biomarker from
Ananas comosus Merr
Eric R. Secor Jr.,1 StevenM. Szczepanek,2 Anurag Singh,3
Linda Guernsey,1 Prabitha Natarajan,1 Karim Rezaul,4 David K. Han,4
Roger S. Thrall,1 and Lawrence K. Silbart5
1Department of Immunology, UConn Health Center, Farmington, CT 06030-1319, USA
2The Carole and Ray Neag Comprehensive Cancer Center, UConn Health Center, Farmington, CT 06030-1628, USA
3Allergy Group, Nestle´ Research Center, P.O. Box 44, 1000 Lausanne, Switzerland
4Center for Vascular Biology, UConn Health Center, Farmington, CT 06030, USA
5Department of Allied Health Sciences, University of Connecticut, Storrs, CT 06269-2101, USA
Correspondence should be addressed to Eric R. Secor Jr., esecor@uchc.edu
Received 25 May 2012; Accepted 2 August 2012
Academic Editor: Vassya Bankova
Copyright © 2012 Eric R. Secor Jr. et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Bromelain (Br) is a cysteine peptidase (GenBank AEH26024.1) from pineapple, with over 40 years of clinical use. The constituents
mediating its anti-inflammatory activity are not thoroughly characterized and no peptide biomarker exists. Our objective is to
characterize Br rawmaterial and identify peptides in the plasma of Br treatedmice. After SDS-PAGE in-gel digestion, Br (VN#3507;
Middletown, CT, USA) peptides were analyzed via LC/MS/MS using 95% protein probability, 95% peptide probability, and a
minimum peptide number= 5. Br spiked mouse plasma (1 ug/ul) and plasma from i.p. treated mice (12mg/kg) were assessed
using SRM. In Br raw material, we identified seven proteins: four proteases, one jacalin-like lectin, and two protease inhibitors. In
Br spiked mouse plasma, six proteins (ananain, bromelain inhibitor, cysteine proteinase AN11, FB1035 precursor, FBSB precursor,
and jacalin-like lectin) were identified. Using LC/MS/MS, we identified the unique peptide, DYGAVNEVK, derived from FB1035,
in the plasma of i.p. Br treated mice. The spectral count of this peptide peaked at 6 hrs and was undetectable by 24 hrs. In this
study, a novel Br peptide was identified in the plasma of treated mice for the first time. This Br peptide could serve as a biomarker
to standardize the therapeutic dose and maximize clinical utility.
1. Introduction
Over 50% of Americans use some form of integrative and
functional medicine with 20% using nutritional supplements
or specific botanical formulations to complement their
health care needs [1]. Concerns relating to the safety and
efficacy of botanicals have increased due to the myriad of
acute and chronic inflammatory conditions they are used
for, either in isolation, or as in most cases, as adjuncts
to pharmacological treatments [2–5]. As development of
new drugs from botanical sources escalates, these products
require confirmation of quality and characterization with
sensitive and rigorous methods such as proteomics and mass
spectrometry [6–9]. Also, the identification of biomarkers in
clinically relevant animal models is critical to both inform
and safely advance opportunities for human treatment [10–
17].
Stem bromelain (Br) is an extract of the common
pineapple Ananas comosus (L.) Merr. and is widely utilized
as an anti-inflammatory compound due to its endogenous
protease activity [18]. Br is categorized as an endopepti-
dase belonging to the Peptidase C1A subfamily (MEROPS
database nomenclature; http://merops.sanger.ac.uk/) and
may refer to a mixture of cysteine proteinases, peroxidases,
acid phosphatases, glycosidases, and inhibitory proteins
found throughout the pineapple fruit (EC 3.4.22.33) and
stem (EC 3.4.22.32) [19, 20]. Historically, Br was identified
as crude heterogeneous protein (2–5 proteolytically active
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components) with molecular mass found to vary between
8 and 28.5 kDa [21–23]. Although the nomenclature for
Br is inconsistent, studies which utilized mass spectrometry
have determined that Br has at least 8 proteolytically
active components. These include stem Br (F4/F5), fruit Br,
ananain (F9) comosain, SBA/a, and SBA/b [24–29].
The degree to which Br and its components are absorbed
and retain function still remains to be fully elucidated. In
experimental models of irritable bowel disease, it has been
reported that the majority of orally administered Br remains
undegraded and retains its enzymatic activity in the intesti-
nal lumen of mice [30]. When administered orally, crude Br
has been identified in human plasma via quantification with
an immunoassay which detects Br antibodies [31]. Several
studies confirm clinical effects of orally administered Br in
cancer [32], rheumatoid arthritis [33], and osteoarthritis
[34]; however, the characterization and detection of the
individual Br peptides has not been reported. In addition,
analytical techniques such as proteomics and LC-MS/MS
have not been routinely applied to evaluate potential in vivo
biomarkers for this botanical drug [35–37].
The purpose of this study was to validate the components
of a clinically used stem Br product, using MS and to
determine if a Br peptide biomarker could be identified in
the plasma of Br treated mice using LC-MS/MS. This is
one of the first studies to report the components within
a clinically used Br product and to identify a Br peptide
(DYGAVNEVK) in plasma. This approach can now be
applied to improve the characterization and quality control
of Br in the marketplace. This biomarker will provide
an important tool for standardizing the effective dose of
the product in order to correlate the absorbed dose with
therapeutic effects attributed to this complex product.
2. Methods
2.1. Bromelain. Br (EC 3.4.22.32; catalog VNBR, lot number
3507) was obtained from RHG& Company Inc., Vital Nutri-
ents (Middletown, CT, USA) and stored at 4◦C in opaque
containers. The identity of Br, extracted from Ananas como-
sus Merr. (common pineapple), was confirmed by matching
its profile with the industry (Sigma) standards (via HPLC) as
previously described [38]. Br was also independently tested
for authenticity, potency, microbial contamination, residual
solvents, heavy metals, and aflatoxins (Venture Laboratories,
Lexington, KY, USA Eastern Analytical Laboratory, Old
Saybrook, CT, USA Pharmline, Florida, NY, USA Covance,
Madison, WI and Chemical Solutions Ltd., Mechanicsburg,
PA, USA).
2.2. Animals. Female C57BL/6J mice, 3 to 6 months of
age and weighing 17 to 20 g, were purchased from the
Jackson Laboratory (Bar Harbor, ME, USA) and housed
conventionally in plastic cages with corncob bedding. The
mouse room was maintained at 22 to 24◦C with a daily
light/dark cycle (light from 0600 to 1800 hours). Chow and
water were supplied ad libitum. All mouse procedures were
approved by the Animal Care Committee at the University of
Connecticut Health Center (protocols 2009-508 and 2010-
634).
2.3. Bromelain Treatment. Individual stock solutions of stem
Br were prepared. For ex vivo spiked serum experiments
100mg Br was suspended in 20ml diH20; 10 μL naı¨ve mouse
serum was spiked with 10 μg Br. For i.p. treatment, 60mg
of Br was suspended in 125mL of physiologic saline as
previously described [39, 40]. Animals received one i.p.
injection of Br (12mg/kg) in 0.5ml of physiological saline
and serum collected at sacrifice over 24 hr time course.
Serum samples were concentrated in 50K Microcon Ultracel
YM-50 (Millipore, Billerica, MA, USA) prior to SRM prep.
2.4. In-Gel Digestion. Br was processed with a modified
RIPA buffer to concentrate plant associated protein and
remove plant associated detritus and 1-dimensional SDS-
PAGE separation was performed on the extract plant protein.
Br samples were loaded into a 10% reducing mini-SDS-
PAGE and separated via electrophoresis for 20min. The gel
lane corresponding to Br was then cut into 13 sections and
subjected to proteolytic digestion on a ProGest workstation
(Genomic Solutions) via reduction with DTT at 60◦C,
followed by a cool down to room temperature. Samples
were then alkylated with iodoacetamide and digested in
trypsin (12.5 μg/mL) at 37◦C for 4 h. Formic acid (5%) was
added to stop the reaction and the supernatant was used for
subsequent analyses.
2.5. LC-MS/MS. Samples were analyzed using nano-ESI with
a ThermoFisher LTQ Orbitrap XL LC/MS/MS. 30 μL of
trypsinized protein supernatant was loaded onto a 5mm,
75 μm ID C12 vented column (Jupiter Proteo, Phenomenex)
at a flow rate of 10 μL/min. A 30min gradient elution
was conducted over a 15 cm, 75 μm ID C12 column at
300 nL/min. For identification of proteins in Br the mass
spectrometer was operated in data-dependent mode in
which the six most abundant ions were selected for MS/MS.
The Orbitrap MS scan was performed at 60,000 FWHM
resolutions as previously described [41, 42].
2.6. Mass Spectrometry Data Analysis. MS/MS data were first
searched using Mascot (http://www.matrixscience.com/)
with the following parameters: type of search MS/MS
ion search, taxonomy-all kingdoms, enzyme-trypsin,
fixed modifications-carbamidomethyl (C), variable
modifications-oxidation (M), acetyl (N-term), pyro-glu (N-
term Q), deamidation (N,Q), mass values-monoisotopic,
protein mass-unrestricted, peptide mass tolerance- ±
10 ppm, fragment mass tolerance- ± 0.5Da, and max missed
cleavages-2. Samples were further analyzed using the Scaffold
algorithm (http://www.proteomesoftware.com/) with the
DAT files generated by Mascot. Positive identification was
determined if a minimum of 5 peptides matched per protein
with minimum probabilities of 95% at the protein level and
95% at the corresponding peptide level.
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2.7. Fractionation of Serum Proteins. In a first step, 10 μL
of mouse serum was diluted by the addition of 490 μL of
PBS and serum proteins were separated by ultrafiltration
using a centrifugal concentrator Centricon YM-50 to obtain
a protein fraction of <50 kDa. The filtrates were concentrated
by TCA precipitation using 72.0 μL of 100%TCA and 15.0 μL
of 10% cholic acid/1mL filtrate. The precipitated pellets were
washed three times with 1mL of acetone. The pellet was
briefly dried at room temperature, and then dissolved in
30.0 μL of 0.05M NaOH supplemented with 5.0 μL of 6X
SDS-PAGE sample buffer and boiled for 5min.
2.8. Serum Sample Preparation and LC-MS/MS Analysis.
Each sample was separated on a 10% NuPage gel (Invit-
rogen).Silver staining was used to detect proteins after
electrophoretic separation on polyacrylamide gels. As no
prominent protein bands were detectable in area of interest,
three gel slices from each lane ranging from 23 to 39 kDa
areas were excised and in-gel trypsin digestion was per-
formed as described previously (1, 2). Samples were then
resuspended in buffer A (5% ACN, 0.4% acetic acid, 0.005%
heptafluorobutyric (HFBA) acid in water) and stored at
−20◦C until further analysis.
The peptide digests were sequenced using a high
throughput tandem mass spectrometer, LTQ ESI ion trap
(ThermoFinnigan, Palo Alto, CA, USA) equipped with a
commercial nanoelectrospray device as described previously
(1, 2). Each sample was directly loaded onto a 10 cm ×
100 μm capillary column packed in-house (Magic C18;
Michrom BioResources, Auburn, CA, USA) by means of a
micro-autosampler (Famos, Dionex, Sunnyvale, CA, USA).
The column was previously equilibrated with solvent A
(5% acetonitrile, 0.4% acetic acid, and 0.005% HFBA).
Peptides were eluted with a linear gradient from 100%
solvent A to 80% solvent B (95% acetonitrile, 0.4% acetic
acid, and 0.005% HFBA) in 85min at an elution rate of
200 nL/min. A Hewlett Packard 1100 solvent delivery system
with flow splitting (Hewlett Packard, Palo Alto, CA, USA)
was used. Peptides were eluted directly into the LTQ ESI
ion trap mass spectrometer equipped with data-dependent
acquisition, and a scan was performed. Each full MS scan
was followed by one MS/MS scan of the most intense peaks
in the full MS spectrum with dynamic exclusion enabled
to allow detection of low abundant peptide ions. Auto
sampler loading, mass spectrometric scan functions, and
HPLC solvent gradients were controlled by the Xcalibur data
system (ThermoFinnigan, Palo Alto, CA, USA).
2.9. Analysis of Serum MS/MS Data. All LC-MS/MS runs
were processed in the following way as described previously
[43, 44]. All the mass spectrometry raw files were converted
to .dat files using Xcalibur software (version 1.4 SR1).
Peak lists were automatically extracted using the extract .ms
program with default parameters, except that filtering was
turned off. All the .dat files were searched against a local
copy of the nonredundant pineapple (Ananas comosus)
database from the NCBI, National Institutes of Health,
and Advanced Biomedical Computing Center using the
SEQUEST algorithm (SEQUEST-PVM version 27 (revision
0)) and SEQUEST parameters were as follows: all the filtering
thresholds were off; mass tolerance of 1.5Da for precursor
ions and 0.5Da for fragment ions; full tryptic constraint
allowing one missed cleavage; allowing oxidization (+16Da)
of methionine. The database search results were processed
using the INTERACT program and filtered with the follow-
ing criteria: Xcorr cutoff values of 1.8, 1.8, and 3.1 for 1+,
2+, and 3+ peptides, respectively, ΔCn ≥ 0.1. Finally, all
potential MS/MS spectral matches were subjected to manual
inspection as a final validation step prior to acceptance as a
valid peptide identification. The spectral count of identified
peptides from three runs of each sample was used for semi-
quantitative measurement of bromelain-mediated events.
3. Results
3.1. Bromelain Identity and Quality Control. In the present
study, the Br raw material was obtained from RHG &
Company Inc., Vital Nutrients imported from Thailand.
Prior to manufacturing, Br was independently tested for
identification and quality. A summary of results is provided
in Table 1. Identification of Br was confirmed via HPLC with
an industry (Sigma) standard. The proteolytic activity (a
measure of potency) of Br was 2931 GDU/gm. All residual
solvents residues (from a total of 51 solvents and 166 chem-
ical analytes) tested were within allowable USP Limits. Raw
material was negative for E. coli, Salmonella, S. aureus, and P.
aeruginosa and below limits for mold yeast (160 CFU/gm;
allowable ≤300/gram) and Enterobacteriaceae (≤10/gram;
allowable ≤10/gram). Aflatoxins (B1, B2, G1, and G2) were
negative and all heavy metals tested (arsenic, lead, cadmium,
and mercury) were below allowable limits.
3.2. Characterization of Bromelain Associated Proteins by
Peptide Sequencing . The overall work flow is represented
in Figure 1. A clinically used Br product was chosen for
analysis (Figure 1(A)). After quality control analysis was
completed, mass spectrometry on raw material was initiated.
Post SDS-PAGE separation (Figure 1(B)) in the region
of the gel corresponding to 8–28 kDa was removed and
processed with trypsin digestion. The resulting peptides were
analyzed by LC/MS/MS (Figure 1(C)), data were processed
in the Scaffold proteome program after which in vivo Br
treatment initiated (Figure 1(D)), and serum was analyzed
(Figure 1(E)). By setting the data filtering limits (protein
probability ≥95%, peptide probability ≥95%, minimum
peptide number = 5), we identified six proteins in Br raw
material (Table 2) with 100% probability of match. Four
were proteases-FBSB precursor, FB1035 precursor, cysteine
proteinase precursor ANll, and Ananain. One was a Br
inhibitor and one a jacalin-like lectin. All proteins were
identified in Br Rawmaterial as well as spiked mouse plasma.
The percentage of amino acid peptide coverage for each
protein (Figures 2(a)–2(f)) is depicted in yellow and sites
of predicted amino acid posttranslational modification were
in green. The ion spectrum (Figure 2(g)) is also shown for
the peptide “DYGAVNEVK” in the FBSB precursor protein.
The DYGAVNEVK peptide had a probability of 100% and a
Mascot ion score of 60.
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Table 1: Bromelain identity and quality control data.
Item profile Specification Result Method
Botanical-pineapple Ananas sp. Ananas comosus Visual
Plant parts used Mature plant stem Mature plant stem Visual
Botanical extract Bromelain Bromelain Maltodextrin diluent
Identification Standard Match (Sigma) Conforms to standard HPLC∗
Activity, potency ≥2400GDU∗∗/gram 2931GDU/gram GDU Assay
Solvent Residues LOQ‡ Limits USP
Methanol 1000 ppm 3000 ppm <1000 ppm Gas chromatography
Ethanol 1000 ppm 5000 ppm <1000 ppm Gas chromatography
Diethyl ether 2 ppm 5000 ppm <2.0 ppm Gas chromatography
Acetone 50 ppm 5000 ppm <50 ppm Gas chromatography
2-Propanol 200 ppm 5000 ppm <1200 ppm Gas chromatography
Dichloromethane 2 ppm 600 ppm <2.0 ppm Gas chromatography
n-Hexane (C6) 2 ppm 290 ppm <2.0 ppm Gas chromatography
Ethyl acetate 20 ppm 5000 ppm <20.0 ppm Gas chromatography
Xylenes (0, M, P, EB) 1 ppm 2170 ppm ≤1.0 ppm Gas chromatography
Microbial Profile (CFU/gm) (CFU/gm)
Total mold and yeast ≤300/gram 160 MLP◦ USP 27
E. coli Negative Negative MLP USP 27
Salmonella Negative Negative MLP USP 27
Enterobacteriaceae ≤10CFU/gram <10/gram MLP USP 27
S. aureus Negative Negative MLP USP 27
P. aeruginosa Negative Negative MLP USP 27
Aflatoxin Profile (B1,B2,G1,G2) Aflatoxins ≤20 ppb Negative HPLC
Heavy metal profile
Arsenic ≤3 ppm <0.50 ± 0.5 ppm ICP-MS!
Lead ≤10 ppm 0.08 ± 0.05 ppm ICP-MS
Cadmium ≤3 ppm <0.25 ± 0.25 ppm ICP-MS
Mercury ≤2 ppm <0.10 ± 0.1 ppm ICP-MS
∗HPLC: high-performance liquid chromatography, ∗∗GDU’s: gelatin dissolving units; LOQ‡: limit of quantification, ◦microbial limit tests; ! ICP-MS:
inductively coupled plasma-mass spectrometry; #CDFA: California Department of Food and Agriculture.
3.3. Identification of Br Peptide Biomarker fromMouse Plasma
after Br Treatment. The identification of Br specific peptides
in Br raw material and ex vivo spiked serum (assessment
of matrix effects) were critical in standardization of LC-
MS/MS for the next phase of experiments, identification,
and quantification of a Br peptide in the plasma of mice
following Br treatment. Plasma was collected and processed,
and the filtrate was analyzed by LC-MS/MS. For the analysis,
the most abundant peak in the chromatograph eluded at
5.54min (Figure 3(a)) and this peptide ion spectrum was
consistent with DYGAVNEVK. The spectral count of peptide
“DYGAVNEVK” fromBr was quantified in sera over the 24 hr
time course, peaking at 6 hr (Figure 3(b)).
4. Discussion
According to the Natural Foods Merchandiser, total natural
products industry sales reached a record $81 billion in 2010
[45]. This widespread consumption of supplements and
botanicals often ignores the issue of safety, consistency, and
efficacy, which are often lacking despite longstanding tradi-
tional uses for select products [46, 47]. Br is a proteolytically
active pineapple extract with decades of over-the-counter use
as anti-inflammatory and digestive aid [18, 21, 32, 39, 48,
49]. Although accessible in numerous product combinations
(with other enzymes, antioxidants, vitamins, minerals, or
botanicals), Br has not been thoroughly characterized and no
biomarker exists to evaluate its absorption or the therapeutic
properties of individual components of the product. Our
objective was to characterize a commercially available Br
product via LC/MS/MS and identify a peptide via SRM in
the plasma of Br treated mice. In this study, Br peptides
were characterized and a marker peptide, DYGAVNEVK,
was quantified in the plasma of Br treated mice. This Br
peptide may serve as a useful biomarker to help standardize
therapeutic dosage and maximize its clinical utility.
4.1. Br Identification and Assessment of Quality. Currently
manufacturers who produce Br supplements are expected to
provide specific details about their ingredients on the label
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Figure 1: Bromelain characterization flow diagram. A clinically used quality verified Br product (A) was processed and electrophoresed
on 1D SDS PAGE mini gel (B). The mobility region was excised and gel digests were analyzed via LC-MS/MS for protein identification.
Production data were searched against all kingdoms of the NCBInr database via Mascot search engine and files were parsed into the Scaffold
proteome program (C). After i.p. Br treatment (D) plasma samples were assed via SRM for presence of Br specific peptides andDYGAVNEVK
was identified and quantified over 24 hrs (E).
Table 2: Bromelain LC/MS/MS protein identification: raw material corresponds to spiked plasma.
Protein name
Accession
number
MW (kDa)
Unique
peptides
Match
probabilty
Sequence aa
coverage
ID in raw material
and plasma
(A) FB1035 precursor gi|2463588 36.2 14 100% 165/356 (46%) Y
(B) Cysteine proteinase precursor N11 gi|3377950 39.6 7 100% 99/357 (28%) Y
(C) Ananain gi|2623956 38.2 11 100% 140/345 (41%) Y
(D) Bromelain inhibitor gi|110282975 27.5 5 100% 50/246 (20%) Y
(E) Jacalin-like lectin gi|33323037 15.5 9 100% 125/145 (86%) Y
(F) FBSB precursor gi|2463584 39.6 14 100% 165/356 (46%) Y
[46, 47]. This includes the amount (mg or gm) delivered
per capsule, the broad nonspecific protein digesting activity
in gelatin digesting units (GDU) or milk clotting units
(MCU), and the presence of other active or nonactive
ingredients such as excipients, binders, or fillers. In addi-
tion, manufacturers should provide a certificate of analysis
which identifies the plant part utilized, extraction method,
and verification of the validity of botanical extract. With
the anticipated enforcement of the DSHEA [50], detailed
results of quality control testing (solvent residues, microbial
contaminants, heavy metals, and pesticide residues) will also
be required [51, 52]. Without this information, the manu-
facturer, physician, and consumer has no detailed knowledge
of the individual constituents being delivered within Br
supplements, nor details of optimal product composition
and variation [52–54]. Moreover, once products such as Br
are ingested, there is no in vivo mechanism (data or bio
markers) for monitoring the absorbed dose or therapeutic
effectiveness of the product.
In order to characterize Br being utilized by consumers,
we chose a commercially available product distributed to
physicians for use in our research. Although there were
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gi|2463588 (100%), 36,038.2 Da
FB1035 precursor [Ananas comosus]
6 unique peptides, 7 unique spectra, 38 total spectra, 145/324 amino acids (45% coverage)
(a)
gi|3377950 (100%), 39,606.9 Da
Cysteine proteinase precursor, AN11 [Ananas comosus]
7 unique peptides, 9 unique spectra, 14 total spectra, 99/357 amino acids (28% coverage)
(b)
gi|13432122 (100%), 38,248.7 Da
RecName: full ananain; flags: precursor, gi |2623956|emb|CAA05487.1| ananain precursor
[Ananas comosus]
11 unique peptides, 15 unique spectra, 72 total spectra, 140/345 amino acids (41% coverage)
=
(c)
gi|110282975 (100%), 27,520.7 Da
contains: RecName: full=bromelain inhibitor 1 chain B;
5 unique peptides, 8 unique spectra, 25 total spectra, 50/246 amino acids (20% coverage)
RecName: full= bromelain inhibitor; short=BI, short= bromein;
(d)
gi|33323037 (100%), 15,478.2 Da
Jacalin-like lectin [Ananas comosus]
9 unique peptides, 13 unique spectra, 52 total spectra, 125/145 amino acids (86% coverage)
(e)
gi|2463584 (100%), 39,560.9 Da
14 unique peptides, 19 unique spectra, 107 total spectra, 165/356 amino acids (46% coverage)
FBSB precursor [Ananas comosus]
(f)
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Figure 3: Bromelain LC-MS/MS and DYGAVNEVK peptide quantification. Individual mice were treated with Br (one–12mg/kg i.p.
injection) and peripheral blood was collected via cardiac puncture at 3, 6, 12, and 24 hrs and processed. Plasma was collected and processed,
and filtrate was analyzed by LC-MS/MS. The total number of spectra of peptide “DYGAVNEVK” from Br protein FB1035 precursor was
identified in sera peaking at 6 hrs over the 24 hr time course.
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several industrial sources available, most are “for research
purposes only” such as Sigma’s and may not represent
the Br manufactured for medicinal use. Also, handling,
testing and consistency of natural products may vary greatly.
The Br we utilized was independently tested by analytical
laboratories for enzymatic activity and contamination from
solvents, microbials, aflatoxins, and heavy metals (Table 1).
Organoleptic techniques, which are still used to identify
pineapple and its mature stem, are combined with HPLC
to confirm the Br extract. Although Br is composed of
both cysteine proteases and inhibitory proteins, only the net
enzymatic activity of Br (2931DU/gm for our lot) is cited
on product labels and the ratio and consistency of individual
proteins is unknown. We are unaware of any other botanical
studies which conduct this level of quality control testing on
clinically used products.
4.2. Peptide Identification and Protein Verification via LC-
MS/MS. Before analysis could be applied to the serum of
i.p. Br treated mice, the peptides and protein(s) present
in Br stem extract had to be identified and verified in
order to choose suitable peptide(s) for use as biomarkers.
Separation of Br raw material via LC and identification
of Br peptides via MS/MS resulted in the identification
of five protease (Figure 2): (1) FB1035 gi2463588, (2) cys-
teine proteinase AN11 gi3377950, (3) gi2623956, (4) FBSB
precursor gi2463584, and (5) stem bromelain gi115139, a
jacalin-like lectin gi33323037, and a Br inhibitor protein
gi110282975 [55, 56]. Two Br protein sequences identified,
VPQSIDWRDSGAVTSVKNQG in ananain and AVPQSID-
WRDYGAVTSVKNQN in FBSB precursor, correspond and
confirm previous investigations on the comparisons of these
N-terminal amino acid sequences performed by Napper
et al. [27]. In our initial analysis we did not identify
the 2KDa cysteine proteinase, comosain which had been
previously described [27, 57, 58]. However, adjusting the
filter limits from a minimum peptide number of 5 down to
2 (protein probability ≥95%, peptide probability ≥95%) did
confirm that in addition to comosain (gi685082, VPQSID-
WRNYG AVTSVKNQG), the Br inhibitor IV H chain
(gi159163781) as well as chitinase A (gi189095136) chitinase
C (gi125995173), and cystatin (gi33323039), were all present
in the Br raw material.
In contrast to stem Br, which has been the subject of
numerous basic and clinical studies, there are very few
studies on individual Br proteins. A novel ananain comosain
combination product, Vianain, has been formulated for
topical wound treatment and debridement due to its
inherent protease activity [59], and the highly purified
bromelain protease F9 (or ananain) has been investigated for
its ability to reduce CD44 mediated adhesion in lymphocytes
[38]. Although the Br specific jacalin-like lectin has
been previously identified (EMBL:AAQ07258.1), no specific
literature exists which describes its distribution and potential
function in Ananas comosus. Similar jacalin-like lectins have
been identified in several plant families (Moraceae-jackfruit,
Gramineae-Triticum aestivum, or wheat) and function
in protein-carbohydrate recognition through cell surface
binding of carbohydrates such as mannose [60]. Jacalin-like
lectins may also have a role clinically as there is evidence
in enhancing pathogen resistance and facilitate binding of
human IgA [61, 62].
Although controversy exists regarding the extent to
which Br is absorbed and present in the serum, Castel
has identified the presence of anti-Br antibodies in human
plasma after oral administration [31] while in separate stud-
ies White and Seifert noted that both orally and intraduo-
denally administered, 125I-labeled Br was absorbed and
present in the serum of rats [63, 64]. However, there are no
reports of unique Br peptide biomarkers present in plasma
following exposure. In order to determine if Br peptides
were present in serum, we utilized LC-MS/MS, a technique
associated with the selective and sensitive detection of small
molecules (<1000Da) which is widely used in clinical,
pharmaceutical, and environmental monitoring fields [65].
As part of the SRM assay process, mouse plasma samples
were spiked with Br and processed using an in-solution
digestion protocol that requires reducing and alkylating the
sample before trypsin digestion and analysis to determine
recovery and evaluate matrix affects. In Br spiked mouse
plasma, six proteins (FB1035 precursor, cysteine proteinase
AN11, ananain, bromelain inhibitor, the jacalin-like lectin,
and FBSB precursor) were identified and correspond to Br
raw material (Table 2).
The unique peptides DYGAVNEVK,
TGYLVSLSEQEVLDCAVSYGCK, and
NSWGSSWGEGGYVR within the FB1035 gi|2463588
protein were previously observed in an LC-MS/MS analysis
of bromelain extract. When plasma from Br treated mice
was evaluated, we identified the DYGAVNEVK biomarker
peptide. The total number of spectra identified or spectral
count for DYGAVNEVK was found to peak at 6 hrs over
the 24 hr time course evaluated after initial intraperitoneal
Br treatment. Although the specific activity of this peptide
is unknown, DYGAVNEVK is present in one of the four
proteolytically active proteins (FB1035) within Br which
contribute to its therapeutic effects. Future studies may
determine the contribution of individual peptides and set
the stage for their use as compounds to standardize Br
beyond its peptidase activity, which is becoming the gold
standard within the botanical extract industry [66–68]. By
utilizing standardized well-established analytic methods
such as LC-MS/MS, we hope to develop a robust, high
throughput assay which has the sensitivity to determine if
protein or peptide ratios vary between distinct Br products
and if this affects their enzymatic activity. In addition, as
Br products are widely used for numerous inflammatory
and immunological conditions, it is critical to quantify Br
peptides for use as potential biomarkers in human samples
as well. This information will provide data for both safety
and efficacy studies as well as optimizing the therapeutic
dose needed for clinical utility.
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